Marleen I. Meyers, MD, discusses how for patients with cancer, diet influences prevention, treatment outcomes, and long-term survivorship.
Videos
Petros Grivas, MD, PhD, discusses challenges in cancer care in the bladder cancer setting.
Alan H. Bryce, MD, discusses areas of need to help guide treatment decisions in the clinic for prostate cancer management.
An expert discusses how monitoring capillary leakage syndrome (CLS) requires vigilant assessment of fluid balance, hemodynamics, and biomarkers. Academic settings may have advanced resources, whereas community settings rely on standardized protocols. Key adverse effects include hypotension, edema, and organ dysfunction. Management includes fluid resuscitation, vasopressors, and close monitoring.
An expert discusses how, for younger/fitter patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), treatment selection as a bridge to transplant is based on efficacy, toxicity, and response depth. Patient-specific (age, comorbidities) and systemic (drug access, center expertise) factors guide decisions. Emerging real-world evidence, such as Berning et al (ASH 2024), highlights CD123-targeted therapy’s role in optimizing response rates before allogeneic stem cell transplantation (allo-SCT).
Wojciech Jurczak, MD, PhD, discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase inhibitors and degraders.
Paul B. Renz, DO, discusses anecdotal changes observed by clinician researchers using the MR-LINAC system.
Paul B. Renz, DO, discusses the ideal uses of magnetic resonance-guided linear accelerator system.
A panelist discusses how recent advancements in molecular diagnostics, targeted therapies, and individualized treatment approaches give them greatest optimism for patients with polycythemia vera (PV) by potentially altering disease trajectory, reducing complications, and significantly improving quality of life and long-term outcomes.
A panelist discusses how available therapeutic strategies have enhanced their approach to treatment sequencing in patients with polycythemia vera (PV) by providing a broader armamentarium that allows for customized stepwise management based on disease characteristics, risk stratification, treatment response, and evolving symptom burden.
Hedy Lee Kindler, MD, shares new mesothelioma guidelines that have been released by the American Society of Clinical Oncology.
Wojciech Jurczak, MD, PhD, discusses advancements in B-cell lymphoma therapy, focusing on immunotherapy, molecular-targeted agents, and more.
Deborah Wong, MD, PhD, discusses therapeutic options for patients with nasopharyngeal carcinoma.
Rodabe Amaria, MD, discusses the current role of OBX-115 for the treatment of patients with checkpoint inhibitor-resistant metastatic melanoma.
Wojciech Jurczak, MD, PhD, discusses nemtabrutinib and its development for the treatment of follicular lymphoma.
An expert discusses how quality-of-life assessments guide treatment strategies for patients with myeloproliferative neoplasms (MPNs).
An expert discusses insights from MAJIC-PV, MANIFEST-2, and other relevant trials and how these studies help advance the management of myeloproliferative neoplasms (MPNs).
Seth Wander, MD, PhD, discusses approved and upcoming targeted therapies for patients with ESR1-mutated breast cancer.
Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or higher.
An expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.
An expert discusses how, for advanced unresectable hepatocellular carcinoma (uHCC), clinicians monitor treatment efficacy through imaging, α-fetoprotein levels, and tolerability. Treatment decisions are guided by response assessment, adverse events, and liver function. First-line (1L) options include tyrosine kinase inhibitors and immunotherapy combinations, with promising trials exploring novel immune combinations and targeted approaches that may reshape the treatment landscape.
An expert discusses other ongoing investigations exploring radium-223-based combinations for the treatment of metastatic castration-resistant prostate cancer, highlighting key studies and their potential impact on clinical practice.
Panelists discuss how emerging evidence suggests that combining transarterial chemoembolization (TACE) with systemic therapy could redefine the standard of care for hepatocellular carcinoma (HCC). Trial outcomes may drive shifts toward more personalized locoregional approaches. However, challenges in implementation include optimizing patient selection, managing toxicity, and ensuring multidisciplinary coordination.
Panelists discuss how the role of systemic therapy in intermediate-stage hepatocellular carcinoma (HCC) is evolving with combinations like immunotherapy and targeted agents enhancing locoregional treatment. LEAP-012 and EMERALD-1 evaluate lenvatinib + pembrolizumab and durvalumab-based regimens with transarterial chemoembolization (TACE), respectively. Their findings may redefine treatment paradigms, improving outcomes and expanding therapeutic options.
An expert discusses what has been learned about the use of bone-protecting agents and bone density scans for patients receiving an androgen receptor pathway inhibitor (ARPI) in combination with radium-223, based on data from the Phase 3 PEACE-3 study (Enza + Ra-223) and the Phase 3 ERA-223 study (AAP + Ra-223).
An expert discusses how in the first-line (1L) treatment of advanced unresectable hepatocellular carcinoma (uHCC) with tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib, proactive adverse event (AE) management is crucial. This includes baseline assessment; regular monitoring of adverse effects such as hypertension, hand-foot syndrome, and fatigue; and implementing preventive strategies. Treatment should be individualized with dose modifications as needed to balance therapeutic efficacy with quality of life, particularly given the advanced disease state.
Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint inhibitor-resistant metastatic melanoma.
An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts treatment selection by offering improved convenience and accessibility, particularly in advanced/metastatic and perioperative settings. SC formulations may reduce costs, time, and patient burden while enhancing treatment compliance and follow-up.
An expert discusses how medical professionals counsel eligible patients about adjuvant immune checkpoint inhibitor (ICI) therapy by discussing its potential to reduce cancer recurrence, emphasizing the benefits in high-risk cases. They carefully assess patient eligibility, explaining potential immune-related adverse events and balancing these risks with the treatment’s potential lifesaving benefits.
Panelists discuss the management of adverse events (AEs) associated with ROS1 inhibition, emphasizing strategies for prevention, monitoring, and treatment of adverse effects.